Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Share-based Compensation: 2015-2025

Historic Share-based Compensation for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $2.5 million.

  • Seres Therapeutics' Share-based Compensation fell 52.11% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 48.83%. This contributed to the annual value of $21.0 million for FY2024, which is 38.50% down from last year.
  • Per Seres Therapeutics' latest filing, its Share-based Compensation stood at $2.5 million for Q3 2025, which was up 6.07% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Share-based Compensation peaked at $13.5 million during Q2 2023, and registered a low of $2.3 million during Q2 2025.
  • Its 3-year average for Share-based Compensation is $5.7 million, with a median of $5.2 million in 2024.
  • As far as peak fluctuations go, Seres Therapeutics' Share-based Compensation spiked by 165.31% in 2021, and later slumped by 58.98% in 2024.
  • Over the past 5 years, Seres Therapeutics' Share-based Compensation (Quarterly) stood at $5.7 million in 2021, then climbed by 28.50% to $7.3 million in 2022, then tumbled by 30.24% to $5.1 million in 2023, then decreased by 25.97% to $3.8 million in 2024, then crashed by 52.11% to $2.5 million in 2025.
  • Its Share-based Compensation stands at $2.5 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.8 million for Q1 2025.